EAGLE, Idaho, June 05, 2024 (GLOBE NEWSWIRE) -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication, product and wellness company, today announced that members of its executive management team will participate in the Oppenheimer 24th Annual Consumer Growth and E-Commerce Conference. A virtual fireside chat will be available on Tuesday, June 11, 2024 at 10:30 a.m. EDT. The live webcast and replay is accessible on the “Investors” section of the Company’s website at www.PetIQ.com.
About PetIQ
PetIQ is a leading pet medication, health and wellness company delivering a smarter way for pet parents to help their pets live their best lives through convenient access to affordable products and veterinary services. The Company's product business engages with pet parents through retail and e-commerce sales channels with its branded and distributed pet medications as well as health and wellness items. PetIQ manufactures and distributes pet products from its world-class facilities in Omaha, Nebraska, Springville, Utah and Daytona Beach, Florida. The Company’s veterinarian services offering operates in over 2,600 mobile community clinic locations and wellness centers hosted at retail partners in 39 states. PetIQ believes that pets are an important part of the family and deserve the best products and care we can provide them.
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. or 208.513.1513
Media: This email address is being protected from spambots. You need JavaScript enabled to view it. or 407.929.6727

| Last Trade: | US$30.98 |
| Daily Volume: | 0 |
| Market Cap: | US$919.180M |
February 11, 2025 August 07, 2024 May 08, 2024 March 14, 2024 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load